{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T04:30:52Z","timestamp":1764131452851},"reference-count":95,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","seminarsinnephrology.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.semnephrol.2016.05.009","type":"journal-article","created":{"date-parts":[[2016,7,28]],"date-time":"2016-07-28T02:15:16Z","timestamp":1469672116000},"page":"331-342","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Established and Emerging Strategies in the Treatment of Chronic Kidney Disease"],"prefix":"10.1016","volume":"36","author":[{"given":"Julio E.","family":"Pena-Polanco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda F.","family":"Fried","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semnephrol.2016.05.009_bib1","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1136\/bmj.293.6545.471","article-title":"Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy","volume":"293","author":"Bj\u00f6rck","year":"1986","journal-title":"BMJ"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib2","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib3","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib4","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib5","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1056\/NEJM199604113341502","article-title":"Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group","volume":"334","author":"Maschio","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib6","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(98)10363-X","article-title":"Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria","volume":"354","author":"Ruggenenti","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib7","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1681\/ASN.2006121372","article-title":"Renoprotection of Optimal Antiproteinuric Doses (ROAD) study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency","volume":"18","author":"Hou","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib8","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-151-1-200907070-00122","article-title":"Effect of telmisartan on renal outcomes: a randomized trial","volume":"151","author":"Mann","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib10","unstructured":"Standards of medical care in diabetes-2015. Diabetes Care 2015;38 Suppl 1:S1-93. Available from: http:\/\/care.diabetesjournals.org\/content\/38\/Supplement_1. Accessed September 9, 2015"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib11","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1053\/j.ajkd.2012.07.005","article-title":"KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 update","volume":"60","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.7326\/0003-4819-151-1-200907070-00120","article-title":"Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials","volume":"151","author":"Bilous","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib13","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1056\/NEJMoa0808400","article-title":"Renal and retinal effects of enalapril and losartan in type 1 diabetes","volume":"361","author":"Mauer","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib14","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa042167","article-title":"Preventing microalbuminuria in type 2 diabetes","volume":"351","author":"Ruggenenti","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib15","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJMoa1007994","article-title":"Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes","volume":"364","author":"Haller","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib16","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/01.ASN.0000051594.21922.99","article-title":"Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study","volume":"14","author":"Mann","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib17","doi-asserted-by":"crossref","first-page":"30","DOI":"10.7326\/0003-4819-148-1-200801010-00190","article-title":"Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease","volume":"148","author":"Kunz","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib18","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib19","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib20","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib21","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.steroids.2009.09.008","article-title":"Aldosterone as a renal growth factor","volume":"75","author":"Thomas","year":"2010","journal-title":"Steroids"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib22","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1681\/ASN.2009070737","article-title":"Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy","volume":"20","author":"Mehdi","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib23","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/S2213-8587(14)70194-9","article-title":"Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial","volume":"2","author":"Ando","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib24","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib25","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib26","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"Evidence-based guideline for the management of high blood pressure in adults","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib27","first-page":"1","article-title":"KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"3","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib28","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJM199403313301301","article-title":"The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group","volume":"330","author":"Klahr","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib29","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib30","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(05)71082-5","article-title":"Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial","volume":"365","author":"Ruggenenti","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib31","unstructured":"SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. [cited 2015 November 9]. Available from: http:\/\/www.nejm.org."},{"key":"10.1016\/j.semnephrol.2016.05.009_bib32","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1053\/j.ajkd.2014.07.030","article-title":"GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration","volume":"64","author":"Levey","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib33","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus","volume":"362","author":"Cushman","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib34","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/ki.2011.415","article-title":"Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients","volume":"81","author":"Ismail-Beigi","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib35","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib36","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/ki.1995.236","article-title":"Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial","volume":"47","year":"1995","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib37","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1001\/jama.290.16.2159","article-title":"Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study","volume":"290","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib38","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1056\/NEJMoa1111732","article-title":"Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes","volume":"365","author":"Boer","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib39","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","author":"UK Prospective diabetes study (UKPDS) group","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib40","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib41","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib42","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(10)60576-4","article-title":"Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial","volume":"376","author":"Ismail-Beigi","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib43","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1093\/eurheartj\/ehq473","article-title":"Hyperuricaemia, chronic kidney disease, and outcomes in heart failure: potential mechanistic insights from epidemiological data","volume":"32","author":"Filippatos","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib44","first-page":"132","article-title":"Uric acid elimination in the urine. Pathophysiological implications","volume":"147","author":"Marangella","year":"2005","journal-title":"Contrib Nephrol"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib45","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1053\/j.ackd.2012.05.004","article-title":"Hyperuricemia and the progression of chronic kidney disease: is uric acid a marker or an independent risk factor?","volume":"19","author":"Nashar","year":"2012","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib46","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1097\/01.ASN.0000034910.58454.FD","article-title":"A role for uric acid in the progression of renal disease","volume":"13","author":"Kang","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib47","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.ajkd.2005.10.006","article-title":"Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level","volume":"47","author":"Siu","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib48","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.2215\/CJN.01580210","article-title":"Effect of allopurinol in chronic kidney disease progression and cardiovascular risk","volume":"5","author":"Goicoechea","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib49","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1053\/j.ajkd.2014.11.016","article-title":"Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial","volume":"65","author":"Goicoechea","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib50","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/s11892-013-0381-0","article-title":"Uric acid lowering to prevent kidney function loss in diabetes: the preventing early renal function loss (PERL) allopurinol study","volume":"13","author":"Maahs","year":"2013","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib51","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1053\/j.ajkd.2005.03.003","article-title":"Metabolic acidosis of CKD: diagnosis, clinical characteristics, and treatment","volume":"45","author":"Kraut","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib52","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1053\/j.ajkd.2009.02.014","article-title":"Serum bicarbonate levels and the progression of kidney disease: a cohort study","volume":"54","author":"Shah","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib53","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/j.1523-1755.2004.00496.x","article-title":"Calcium citrate ameliorates the progression of chronic renal injury","volume":"65","author":"Gadola","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib54","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3109\/08860229809045124","article-title":"Oral sodium bicarbonate reduces proximal renal tubular peptide catabolism, ammoniogenesis, and tubular damage in renal patients","volume":"20","author":"Rustom","year":"1998","journal-title":"Ren Fail"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib55","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1681\/ASN.2008111205","article-title":"Bicarbonate supplementation slows progression of CKD and improves nutritional status","volume":"20","author":"de Brito-Ashurst","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib56","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/ki.2010.129","article-title":"Daily oral sodium bicarbonate preserves glomerular filtration rate by slowing its decline in early hypertensive nephropathy","volume":"78","author":"Mahajan","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib57","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/ki.2009.519","article-title":"Amelioration of metabolic acidosis in patients with low GFR reduced kidney endothelin production and kidney injury, and better preserved GFR","volume":"77","author":"Phisitkul","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib58","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/ndt\/gfn633","article-title":"Association of serum bicarbonate levels with mortality in patients with non-dialysis-dependent CKD","volume":"24","author":"Kovesdy","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib59","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1053\/j.ajkd.2013.01.017","article-title":"Association of serum bicarbonate with risk of renal and cardiovascular outcomes in CKD: a report from the Chronic Renal Insufficiency Cohort (CRIC) study","volume":"62","author":"Dobre","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib60","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0272-6386(97)90004-4","article-title":"Endothelins in the normal and diseased kidney","volume":"29","author":"Kohan","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib61","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ki.1996.397","article-title":"An orally active ETA\/ETB receptor antagonist ameliorates proteinuria and glomerular lesions in rats with proliferative nephritis","volume":"50","author":"G\u00f3mez-Garre","year":"1996","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib62","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1067\/mlc.2000.105972","article-title":"Reactive oxygen species and endothelins in diabetic nephropathy","volume":"135","author":"Kohan","year":"2000","journal-title":"J Lab Clin Med"},{"issue":"Suppl 3","key":"10.1016\/j.semnephrol.2016.05.009_bib63","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1365-2362.2006.01689.x","article-title":"Role of endothelin and endothelin receptor antagonists in renal disease","volume":"36","author":"Neuhofer","year":"2006","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib64","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1681\/ASN.2006030208","article-title":"Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism","volume":"18","author":"Sasser","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib65","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s00125-009-1540-3","article-title":"The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice","volume":"53","author":"Watson","year":"2010","journal-title":"Diabetologia"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib66","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1681\/ASN.2008050482","article-title":"Avosentan reduces albumin excretion in diabetics with macroalbuminuria","volume":"20","author":"Wenzel","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib67","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1681\/ASN.2009060593","article-title":"Avosentan for overt diabetic nephropathy","volume":"21","author":"Mann","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib68","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.lfs.2012.01.011","article-title":"Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD)","volume":"91","author":"Andress","year":"2012","journal-title":"Life Sci"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib69","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1681\/ASN.2013080830","article-title":"The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy","volume":"25","author":"de Zeeuw","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib70","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.2215\/CJN.00570115","article-title":"Predictors of atrasentan-associated fluid retention and change in albuminuria in patients with diabetic nephropathy","volume":"10","author":"Kohan","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib71","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1445-5994.2011.02439.x","article-title":"Incretin-based therapies--review of the physiology, pharmacology and emerging clinical experience","volume":"41","author":"Martin","year":"2011","journal-title":"Intern Med J"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib72","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1042\/CS20120167","article-title":"Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease","volume":"124","author":"Panchapakesan","year":"2013","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib73","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1681\/ASN.2006070778","article-title":"Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db\/db mice","volume":"18","author":"Park","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib74","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1124\/jpet.111.186866","article-title":"Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats","volume":"340","author":"Liu","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib75","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.bbrc.2013.12.049","article-title":"Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes","volume":"443","author":"Kodera","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib76","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/1471-2369-14-98","article-title":"Dipeptidyl peptidase IV inhibitor attenuates kidney injury in rat remnant kidney","volume":"14","author":"Joo","year":"2013","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib77","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1507\/endocrj.EJ13-0305","article-title":"DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1\u03b1 in type 2 diabetic patients with incipient nephropathy","volume":"61","author":"Fujita","year":"2014","journal-title":"Endocr J"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib78","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000341487","article-title":"DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy","volume":"36","author":"Alter","year":"2012","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib79","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib80","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.2337\/dc13-0323","article-title":"Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction","volume":"36","author":"Groop","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib81","first-page":"3","article-title":"Extra-glycaemic properties of empagliflozin","volume":"25","author":"Solini","year":"2015","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib82","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib83","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib84","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0272-6386(99)70182-4","article-title":"Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration","volume":"33","author":"Navarro","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib85","first-page":"790","article-title":"The effect of pentoxifylline on reduction of proteinuria among patients with type 2 diabetes under blockade of angiotensin system: a double blind and randomized clinical trial","volume":"32","author":"Ghorbani","year":"2012","journal-title":"Nefrologia"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib86","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1681\/ASN.2005010001","article-title":"Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial","volume":"16","author":"Navarro","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib87","doi-asserted-by":"crossref","first-page":"969","DOI":"10.5301\/jn.5000077","article-title":"Effects of pentoxifylline on inflammatory parameters in chronic kidney disease patients: a randomized trial","volume":"25","author":"Goicoechea","year":"2012","journal-title":"J Nephrol"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib88","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1681\/ASN.2014010012","article-title":"Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial","volume":"26","author":"Navarro-Gonz\u00e1lez","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib89","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.abb.2003.08.021","article-title":"Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications","volume":"419","author":"Metz","year":"2003","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib90","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1159\/000108104","article-title":"Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy","volume":"27","author":"Williams","year":"2007","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib91","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1681\/ASN.2011030272","article-title":"Pyridorin in type 2 diabetic nephropathy","volume":"23","author":"Lewis","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib92","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1093\/ndt\/gfq313","article-title":"The expanding spectrum of biological actions of vitamin D","volume":"25","author":"Rojas-Rivera","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib93","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1161\/HYPERTENSIONAHA.108.113159","article-title":"Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial","volume":"52","author":"Alborzi","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib94","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1053\/j.ajkd.2009.04.036","article-title":"Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial","volume":"54","author":"Fishbane","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2016.05.009_bib95","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S0140-6736(10)61032-X","article-title":"Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial","volume":"376","author":"de Zeeuw","year":"2010","journal-title":"Lancet"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929516300389?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929516300389?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T02:22:10Z","timestamp":1536546130000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929516300389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":95,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0270929516300389"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2016.05.009","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Established and Emerging Strategies in the Treatment of Chronic Kidney Disease","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nephrology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semnephrol.2016.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}